Isolation and Characterization of E8 Monoclonal Antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine with Efficient Neutralization of Authentic Monkeypox Virus
Open Access
Abstract
Background/Objectives: Monkeypox, twice declared a public health emergency of international concern by the WHO, currently lacks approved targeted therapeutics. This study focused on the development of monkeypox virus (MPXV) E8-specific human monoclonal antibodies (mAbs) derived from recipients of the recombinant vaccinia vaccine (rTV), with subsequent evaluation of their cross-neutralizing activity against orthopoxviruses, including the vaccinia virus (VACV) and MPXV. Methods: Three mAbs (C5, C9, and F8) were isolated from rTV vaccinees. Structural mapping characterized their binding domains on the MPXV E8 and VACV D8 proteins. Neutralization potency was assessed against the VACV TianTan strain and MPXV clade IIb. A combo was further evaluated in a VACV-infected mice model for clinical recovery and viral load reduction. Complement-dependent enhancement mechanisms were also investigated in vitro. Results: C9 targets the virion surface region of E8 and both the virion surface region and intravirion region of D8, showing cross-neutralization activity against the MPXV (IC50 = 3.0 μg/mL) and VACV (IC50 = 51.1 ng/mL) in vitro. All three antibodies demonstrated potent neutralization against the VACV in vitro: C5 (IC50 = 3.9 ng/mL), C9 (IC50 = 51.1 ng/mL), and F8 (IC50 = 101.1 ng/mL). Notably, complement enhanced neutralization against the VACV by >50-fold, although no enhancement was observed for the MPXV. In vivo administration accelerated clinical recovery by 24 h and achieved significant viral clearance (0.9-log reduction). Conclusions: E8-targeting mAbs exhibited broad-spectrum neutralization against orthopoxviruses, demonstrating therapeutic potential against both historical (VACV) and emerging (MPXV) pathogens. However, MPXV’s resistance to complement-dependent enhancement highlights the necessity for pathogen-adapted optimization. These findings establish E8 as a critical conserved target for pan-poxvirus VACV and MPXV countermeasure development.Keywords
Funding Information
- National Natural Science Foundation of China (2024YFC2309504, 2023AFQN001, 2024NITFID805)
- Young Scholar Science Foundation of National Center for STD/AIDS Control and Prevention, Chinese Center for Disease Control and Prevention (2024YFC2309504, 2023AFQN001, 2024NITFID805)
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (2024YFC2309504, 2023AFQN001, 2024NITFID805)
This publication has 50 references indexed in Scilit:
- The Resurgence of Mpox in AfricaJAMA, 2024
- Evaluation of monkeypox‐ and vaccinia‐virus neutralizing antibodies before and after smallpox vaccination: A sero‐epidemiological studyJournal of Medical Virology, 2024
- Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese populationCell Reports, 2023
- Clinical features, treatment, and outcomes of mpox in solid organ transplant recipients: A multicenter case series and literature reviewAmerican Journal of Transplantation, 2023
- Monkeypox: A comprehensive review of a multifaceted virusInfectious Medicine, 2023
- Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus InfectionsCell, 2016
- Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese DonorImmunity, 2016
- Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 NeutralizationCell, 2013
- Antibody Neutralization of the Extracellular Enveloped Form of Vaccinia VirusVirology, 2001
- A Myristylated Membrane Protein Encoded by the Vaccinia Virus L1R Open Reading Frame Is the Target of Potent Neutralizing Monoclonal AntibodiesVirology, 1995